Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Oct;94(4):1577–1584. doi: 10.1172/JCI117499

Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.

T J Neale 1, P P Ojha 1, M Exner 1, H Poczewski 1, B Rüger 1, J L Witztum 1, P Davis 1, D Kerjaschki 1
PMCID: PMC295315  PMID: 7929834

Abstract

Passive Heymann nephritis (PHN) is a model of human membranous nephropathy that is characterized by formation of granular subepithelial immune deposits in the glomerular capillary wall which results in complement activation. This is causally related to damage of the filtration barrier and subsequent proteinuria. The local accumulation of injurious reactive oxygen species (ROS) is a major effector mechanism in PHN. ROS may induce tissue damage by initiating lipid peroxidation (LPO). In turn, this leads to adduct formation between breakdown products of LPO with structural proteins, such as formation of malondialdehyde (MDA) or 4-hydroxynonenal-lysine adducts. To examine the role of LPO in the development of proteinuria we have localized MDA and 4-hydroxynonenal-lysine adducts in glomeruli of PHN rats by immunofluorescence microscopy, using specific monoclonal antibodies. By immunogold electron microscopy, MDA adducts were localized to cytoplasmic vesicles and cell membranes of glomerular epithelial cells, to the glomerular basement membrane (GBM), and also to immune deposits. Type IV collagen was specifically identified as being modified by MDA adducts, using a variety of techniques. Collagenase pretreatment of GBM extracts indicated that the NC-1 domain of type IV collagen was a site of adduct formation. When LPO was inhibited by pretreatment of PHN rats with the antioxidant probucol, proteinuria was reduced by approximately 85%, and glomerular immunostaining for dialdehyde adducts was markedly reduced, even though the formation of immune deposits was not affected. By contrast, lowering of the serum cholesterol levels had no influence on the development of proteinuria. These findings are consistent with the premise that ROS-induced glomerular injury in PHN involves LPO and that this results not only in damage of cell membranes but in modification of type IV collagen in the GBM as well. The close temporal correlation of the occurrence of LPO with proteinuria and the ability of probucol to inhibit proteinuria support a causal role for LPO in the the alteration of the glomerular permselectivity which results in proteinuria.

Full text

PDF
1577

Images in this article

1579Image
on p.1579
1580Image
on p.1580
1580Image
on p.1580
1580Image
on p.1580
1581Image
on p.1581
1581Image
on p.1581
1581Image
on p.1581

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  2. Butkowski R. J., Langeveld J. P., Wieslander J., Hamilton J., Hudson B. G. Localization of the Goodpasture epitope to a novel chain of basement membrane collagen. J Biol Chem. 1987 Jun 5;262(16):7874–7877. [PubMed] [Google Scholar]
  3. Carew T. E., Schwenke D. C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725–7729. doi: 10.1073/pnas.84.21.7725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chisolm G. M., Irwin K. C., Penn M. S. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes. 1992 Oct;41 (Suppl 2):61–66. doi: 10.2337/diab.41.2.s61. [DOI] [PubMed] [Google Scholar]
  5. Couser W. G. Mediation of immune glomerular injury. J Am Soc Nephrol. 1990 Jul;1(1):13–29. doi: 10.1681/ASN.V1113. [DOI] [PubMed] [Google Scholar]
  6. Couser W. G., Salant D. J. In situ immune complex formation and glomerular injury. Kidney Int. 1980 Jan;17(1):1–13. doi: 10.1038/ki.1980.1. [DOI] [PubMed] [Google Scholar]
  7. Diamond J. R. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991 Apr;31:S29–S34. [PubMed] [Google Scholar]
  8. Esterbauer H., Jürgens G., Quehenberger O., Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res. 1987 May;28(5):495–509. [PubMed] [Google Scholar]
  9. Fong L. G., Parthasarathy S., Witztum J. L., Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res. 1987 Dec;28(12):1466–1477. [PubMed] [Google Scholar]
  10. Grond J., Weening J. J., Elema J. D. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest. 1984 Sep;51(3):277–285. [PubMed] [Google Scholar]
  11. Houglum K., Filip M., Witztum J. L., Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest. 1990 Dec;86(6):1991–1998. doi: 10.1172/JCI114934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnson R. J., Klebanoff S. J., Ochi R. F., Adler S., Baker P., Sparks L., Couser W. G. Participation of the myeloperoxidase-H2O2-halide system in immune complex nephritis. Kidney Int. 1987 Sep;32(3):342–349. doi: 10.1038/ki.1987.215. [DOI] [PubMed] [Google Scholar]
  13. Kawamura T., Yoshioka T., Bills T., Fogo A., Ichikawa I. Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries. Kidney Int. 1991 Aug;40(2):291–301. doi: 10.1038/ki.1991.213. [DOI] [PubMed] [Google Scholar]
  14. Kaysen G. A. Hyperlipidemia of the nephrotic syndrome. Kidney Int Suppl. 1991 Apr;31:S8–15. [PubMed] [Google Scholar]
  15. Kerjaschki D., Farquhar M. G. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5557–5561. doi: 10.1073/pnas.79.18.5557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kerjaschki D. Molecular pathogenesis of membranous nephropathy. Kidney Int. 1992 Apr;41(4):1090–1105. doi: 10.1038/ki.1992.166. [DOI] [PubMed] [Google Scholar]
  17. Kerjaschki D., Poczewski H., Dekan G., Horvat R., Balzar E., Kraft N., Atkins R. C. Identification of a major sialoprotein in the glycocalyx of human visceral glomerular epithelial cells. J Clin Invest. 1986 Nov;78(5):1142–1149. doi: 10.1172/JCI112694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kerjaschki D., Sawada H., Farquhar M. G. Immunoelectron microscopy in kidney research: some contributions and limitations. Kidney Int. 1986 Aug;30(2):229–245. doi: 10.1038/ki.1986.175. [DOI] [PubMed] [Google Scholar]
  19. Kerjaschki D., Ullrich R., Diem K., Pietromonaco S., Orlando R. A., Farquhar M. G. Identification of a pathogenic epitope involved in initiation of Heymann nephritis. Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11179–11183. doi: 10.1073/pnas.89.23.11179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Modi K. S., Morrissey J., Shah S. V., Schreiner G. F., Klahr S. Effects of probucol on renal function in rats with bilateral ureteral obstruction. Kidney Int. 1990 Nov;38(5):843–850. doi: 10.1038/ki.1990.280. [DOI] [PubMed] [Google Scholar]
  21. Neale T. J., Ullrich R., Ojha P., Poczewski H., Verhoeven A. J., Kerjaschki D. Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3645–3649. doi: 10.1073/pnas.90.8.3645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Palinski W., Rosenfeld M. E., Ylä-Herttuala S., Gurtner G. C., Socher S. S., Butler S. W., Parthasarathy S., Carew T. E., Steinberg D., Witztum J. L. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989 Feb;86(4):1372–1376. doi: 10.1073/pnas.86.4.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Palinski W., Ylä-Herttuala S., Rosenfeld M. E., Butler S. W., Socher S. A., Parthasarathy S., Curtiss L. K., Witztum J. L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990 May-Jun;10(3):325–335. doi: 10.1161/01.atv.10.3.325. [DOI] [PubMed] [Google Scholar]
  24. Parthasarathy S., Young S. G., Witztum J. L., Pittman R. C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986 Feb;77(2):641–644. doi: 10.1172/JCI112349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Reeders S. T. Molecular genetics of hereditary nephritis. Kidney Int. 1992 Sep;42(3):783–792. doi: 10.1038/ki.1992.348. [DOI] [PubMed] [Google Scholar]
  26. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973 Dec;19(12):1350–1356. [PubMed] [Google Scholar]
  27. Shah S. V. Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol. 1988 Mar;254(3 Pt 2):F337–F344. doi: 10.1152/ajprenal.1988.254.3.F337. [DOI] [PubMed] [Google Scholar]
  28. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 1991 Sep;84(3):1420–1425. doi: 10.1161/01.cir.84.3.1420. [DOI] [PubMed] [Google Scholar]
  29. Steinbrecher U. P., Fisher M., Witztum J. L., Curtiss L. K. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res. 1984 Oct;25(10):1109–1116. [PubMed] [Google Scholar]
  30. Tokuyasu K. T. Use of poly(vinylpyrrolidone) and poly(vinyl alcohol) for cryoultramicrotomy. Histochem J. 1989 Mar;21(3):163–171. doi: 10.1007/BF01007491. [DOI] [PubMed] [Google Scholar]
  31. Turner N., Mason P. J., Brown R., Fox M., Povey S., Rees A., Pusey C. D. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest. 1992 Feb;89(2):592–601. doi: 10.1172/JCI115625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Urien S., Riant P., Albengres E., Brioude R., Tillement J. P. In vitro studies on the distribution of probucol among human plasma lipoproteins. Mol Pharmacol. 1984 Sep;26(2):322–327. [PubMed] [Google Scholar]
  33. Verhoeven A. J., Bolscher B. G., Meerhof L. J., van Zwieten R., Keijer J., Weening R. S., Roos D. Characterization of two monoclonal antibodies against cytochrome b558 of human neutrophils. Blood. 1989 May 1;73(6):1686–1694. [PubMed] [Google Scholar]
  34. Verroust P. J. Kinetics of immune deposits in membranous nephropathy. Kidney Int. 1989 Jun;35(6):1418–1428. doi: 10.1038/ki.1989.143. [DOI] [PubMed] [Google Scholar]
  35. Witztum J. L. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J. 1993 Jan;69(1 Suppl):S12–S18. doi: 10.1136/hrt.69.1_suppl.s12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Witztum J. L., Steinbrecher U. P., Fisher M., Kesaniemi A. Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci U S A. 1983 May;80(9):2757–2761. doi: 10.1073/pnas.80.9.2757. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES